Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

2.50
Hdl Handle:
http://hdl.handle.net/11287/595438
Title:
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Authors:
James, N D; Sydes, M R; Clarke, N W; Mason, M D; Dearnaley, D P; Spears, M R; Ritchie, A W S; Parker, C C; Russell, J M; Attard, G; de Bono, J; Cross, W; Jones, R J; Thalmann, G; Amos, C; Matheson, D; Millman, R; Alzouebi, M; Beesley, S; Birtle, A J; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Cook, A; Elliott, T; Gale, J; Gibbs, S; Graham, J D; Hetherington, J; Hughes, R; Laing, R; McKinna, F; McLaren, D B; O'Sullivan, J M; Parikh, Oi; Peedell, C; Protheroe, A; Robinson, A J; Srihari, N; Srinivasan, Rajaguru; Staffurth, J; Sundar, S; Tolan, S; Tsang, D; Wagstaff, J; Parmar, M K B
Abstract:
Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting first-line long-term hormone therapy. We report primary survival results for three research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care versus standard of care alone.
Citation:
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 2016 Lancet 387: 10024, 1163-1177.
Publisher:
Elsevier
Journal:
Lancet (London, England)
Issue Date:
21-Dec-2015
URI:
http://hdl.handle.net/11287/595438
DOI:
10.1016/S0140-6736(15)01037-5
PubMed ID:
26719232
Additional Links:
http://www.sciencedirect.com/science/article/pii/S0140673615010375
Note:
The article is available via Open Access. Click on the 'Additional Link' above to access the full-text.
Type:
Journal Article
ISSN:
1474-547X
Appears in Collections:
2015 RD&E publications; Oncology

Full metadata record

DC FieldValue Language
dc.contributor.authorJames, N Den
dc.contributor.authorSydes, M Ren
dc.contributor.authorClarke, N Wen
dc.contributor.authorMason, M Den
dc.contributor.authorDearnaley, D Pen
dc.contributor.authorSpears, M Ren
dc.contributor.authorRitchie, A W Sen
dc.contributor.authorParker, C Cen
dc.contributor.authorRussell, J Men
dc.contributor.authorAttard, Gen
dc.contributor.authorde Bono, Jen
dc.contributor.authorCross, Wen
dc.contributor.authorJones, R Jen
dc.contributor.authorThalmann, Gen
dc.contributor.authorAmos, Cen
dc.contributor.authorMatheson, Den
dc.contributor.authorMillman, Ren
dc.contributor.authorAlzouebi, Men
dc.contributor.authorBeesley, Sen
dc.contributor.authorBirtle, A Jen
dc.contributor.authorBrock, Sen
dc.contributor.authorCathomas, Ren
dc.contributor.authorChakraborti, Pen
dc.contributor.authorChowdhury, Sen
dc.contributor.authorCook, Aen
dc.contributor.authorElliott, Ten
dc.contributor.authorGale, Jen
dc.contributor.authorGibbs, Sen
dc.contributor.authorGraham, J Den
dc.contributor.authorHetherington, Jen
dc.contributor.authorHughes, Ren
dc.contributor.authorLaing, Ren
dc.contributor.authorMcKinna, Fen
dc.contributor.authorMcLaren, D Ben
dc.contributor.authorO'Sullivan, J Men
dc.contributor.authorParikh, Oien
dc.contributor.authorPeedell, Cen
dc.contributor.authorProtheroe, Aen
dc.contributor.authorRobinson, A Jen
dc.contributor.authorSrihari, Nen
dc.contributor.authorSrinivasan, Rajaguruen
dc.contributor.authorStaffurth, Jen
dc.contributor.authorSundar, Sen
dc.contributor.authorTolan, Sen
dc.contributor.authorTsang, Den
dc.contributor.authorWagstaff, Jen
dc.contributor.authorParmar, M K Ben
dc.date.accessioned2016-02-02T13:09:19Zen
dc.date.available2016-02-02T13:09:19Zen
dc.date.issued2015-12-21en
dc.identifier.citationAddition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 2016 Lancet 387: 10024, 1163-1177.en
dc.identifier.issn1474-547Xen
dc.identifier.pmid26719232en
dc.identifier.doi10.1016/S0140-6736(15)01037-5en
dc.identifier.urihttp://hdl.handle.net/11287/595438en
dc.description.abstractLong-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting first-line long-term hormone therapy. We report primary survival results for three research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care versus standard of care alone.en
dc.languageENGen
dc.publisherElsevieren
dc.relation.urlhttp://www.sciencedirect.com/science/article/pii/S0140673615010375en
dc.rightsArchived with thanks to Lancet (London, England). Open Access article distributed under the terms of CC BY.en
dc.subjectWessex Classification Subject Headings::Oncology. Pathology.en
dc.titleAddition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.en
dc.typeJournal Articleen
dc.identifier.journalLancet (London, England)en
dc.description.noteThe article is available via Open Access. Click on the 'Additional Link' above to access the full-text.en
dc.type.versionIn press (epub ahead of print)en

Related articles on PubMed

All Items in RD&E Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.